Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Hematology and Cell Therapy

Issue 6/1997

Content (6 Articles)

Review article

Etiopathogeny, prognosis and therapy of myelodysplastic syndromes

G. F. Sanz, M. A. Sanz, T. Vallespi

Original articles

Thrombosis in congenital deficiencies of AT III, protein C or protein S: a study of 44 children

N. H. Toumi, F. Khaldi, S. Ben Becheur, A. Hammou, B. Bouttière, J. Sampol, K. Boukef

Original articles

Repopulation of circulating T, B and NK lymphocytes following bone marrow and blood stem cell transplantation

A. Parrado, S. Casares, J. Prieto, M. Carmona, A. Vaquero, J. M. Rodríguez-Fernández

Original articles

Hemopoietic stem cell proliferation in Belgrade rats: to complete the parable

Z. Ivanovic

Original articles

Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products

S. Hermouet, A.-E. Niaussat, A. Briec, D. Pineau, N. Robillard, R. Bataille, N. Milpied, J.-L. Harousseau, B. Mahé

Case report

Central nervous system relapses after autologous stem cell transplantation for myeloma. Report of two cases

A. Veinstein, A. Brizard, E. Randriamalala, P. Babin, J.-L. Preud’homme, F. Guilhot

Nov 97
Issue: 7/1997

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits